Table 1 Baseline characteristics
Characteristics | No. of patients (%) |
|---|---|
Age (yr) | |
 Median | 64.57 |
 Range | 39.2–87.1 |
Histological type | |
 HGSC | 120 (90.9%) |
 Endometrioid | 1 (0.8%) |
 Undifferentiated | 2 (1.5%) |
 Not specified | 9 (6.8%) |
FIGO stage | |
 IIIC | 90 (68.2%) |
 IV | 41 (31.1%) |
 Not specified | 1 (0.8%) |
Regimen of NAC | |
 Taxane+carboplatin | 113 (85.6%) |
 Other | 16 (12.1%) |
 Not specified | 3 (2.3%) |
Debulking surgery | |
 Yes | 103 (78%) |
 No | 29 (22%) |
ECOG score | |
 0–1 | 93 (70.4%) |
 2–3 | 25 (18.9%) |
 4 | 2 (1.5%) |
 Not specified | 12 (9.1%) |
NLR | |
 ≤ 3 | 37 (28%) |
 > 3 | 95 (72%) |
CRS | |
 CRS1/2 | 50 (68.5%) |
 CRS3 | 23 (31.5%) |
Debulking | |
 Optimal | 60 (58.2%) |
 Suboptimal | 33 (32%) |
 Not specified | 10 (9.7%) |
BRCA testing | |
 Yes | 46 (34.8%) |
 No | 85 (64.4%) |
 Not specified | 1 (0.8%) |
BRCA mutation | |
 Yes | 11 (8.3%) |
 No | 36 (27.3%) |
 Unknown | 85 (64.4%) |
Bevacizumab treatment | |
 Yes | 42 (31.8%) |
 No | 74 (56.1%) |
 Not specified | 16 (12.1%) |